A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- AstraZeneca
- 入组人数
- 893
- 试验地点
- 509
- 主要终点
- Phase III: 1. Progression Free Survival (PFS).
研究概览
简要总结
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
详细描述
This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer. Although the dosing regimens of capivasertib + fulvestrant and of CDK4/6i + fulvestrant are established separately, the dose and schedule for the triplet combinations (capivasertib + CDK4/6i + fulvestrant) need to be confirmed. Therefore, the initial dose finding Phase Ib part of the study will determine the recommended Phase III doses (RP3D) of the triplet combinations. The Phase III part of the study will evaluate the efficacy, safety and the degree of added benefit of the triplet combinations of capivasertib and fulvestrant with investigator's choice of CDK4/6i (either palbociclib or ribociclib at safe and tolerable doses, once identified) in comparison with a control arm (fulvestrant + investigator's choice of CDK4/6i [palbociclib or ribociclib]) in a ER+ HER2- maC high risk population that did not receive prior endocrine therapy in the advanced setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •for both phases:
- •Adult females (pre-/peri-/ and post-menopausal), and adult males.
- •Histologically confirmed HR+/ HER2- breast cancer determined from the most recent tumour sample (primary or metastatic) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.
- •Eligible for fulvestrant therapy and at least one of the following: palbociclib, ribociclib, or abemaciclib, as per local investigator assessment. Previous tolerance to specific CDK4/6 inhibitors and dose levels required.
- •Adequate organ and bone marrow functions.
- •Consent to provide a mandatory FFPE tumour sample.
- •Key inclusion criteria only for phase III:
- •Previous treatment with an ET (tamoxifen, AI, or oral SERD) as a single agent or in combination, with radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen.
- •Provision of mandatory blood samples at screening for central testing using an investigational ctDNA test to be stratified based on PIK3CA/AKT1/PTEN status.
- •Be eligible for fulvestrant and at least one out of palbociclib or ribociclib (depending on the available CDK4/6i options at time of enrolment), as per local investigator assessment.
- •Have measurable lesion(s) according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1) or, in the absence of measurable disease, lytic or mixed bone lesions that can be assessed by computed tomography (CT) or magnetic resonance imaging (MRI).
排除标准
- •for both phases:
- •History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence.
- •Radiotherapy within 2 weeks prior to study treatment initiation.
- •Major surgery or significant traumatic injury within 4 weeks of the first dose of study treatment.
- •Persistent toxicities (CTCAE Grade >1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss or peripheral sensory neuropathy) after consultation with the AstraZeneca study physician.
- •Spinal cord compression, brain metastases or leptomeningeal metastases unless these lesions are definitively treated (eg. radiotherapy, surgery) and clinically stable off steroids for management of symptoms for at least 4 weeks prior to study treatment initiation.
- •Any of the following cardiac criteria at screening:
- •(a). Mean resting corrected QT interval (QTcF): (i) Participants to be treated with palbociclib:: QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (ii) Participants to be treated with ribociclib: QTcF ≥ 450 ms obtained from the average of 3 consecutive (triplicate) ECGs (iii) Participants to be treated with abemaciclib (Phase Ib only): QTcF ≥ 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (b). Any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) (c). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (d). Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) grade ≥ 2 (e). Uncontrolled hypotension (f) uncontrolled hypertension (g). Cardiac ejection fraction outside institutional range of normal or < 50% (whichever is higher)
- •uncontrolled or high grade or symptomatic arrhythmia and atrial fibrillation
- •Any of these clinically significant abnormalities of glucose metabolism at screening:
- •. diabetes mellitus type I or type II requiring insulin treatment
- •. Glycated haemoglobin (HbA1c) ≥ 8.0% (63.9 mmol/mol)
- •Previous allogeneic bone marrow transplant or solid organ transplant.
- •Key exclusion criteria for the phase III only:
- •Any prior treatment with, AKT, PI3K or mTOR inhibitors.
- •Prior treatment with CDK4/6 inhibitors in the metastatic setting (prior CDK4/6 inhibitors permitted in the adjuvant setting provided there was a CDK4/6i treatment free interval of at least 12 months).
- •More than 1 line of chemotherapy for metastatic disease.
- •Any line of endocrine-based therapy for inoperable locally advanced or metastatic disease.
研究组 & 干预措施
Capivasertib Plus Abemaciclib and Fulvestrant
Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b)
干预措施: Abemaciclib (Drug)
Capivasertib Plus Palbociclib and Fulvestrant
Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)
干预措施: Capivasertib (Drug)
Capivasertib Plus Ribociclib and Fulvestrant
Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b)
干预措施: Ribociclib (Drug)
Capivasertib Plus Palbociclib and Fulvestrant
Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)
干预措施: Palbociclib (Drug)
Capivasertib Plus Palbociclib and Fulvestrant
Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)
干预措施: Fulvestrant (Drug)
Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)
Fulvestrant and investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)
干预措施: Fulvestrant (Drug)
Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)
Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)
干预措施: Capivasertib (Drug)
结局指标
主要结局
Phase III: 1. Progression Free Survival (PFS).
时间窗: Up to approximately 47 months.
Progression Free Survival (PFS) is defined as time from randomization until progression per RECIST v1.1. as assessed by BICR or death due to any cause in the overall population, the altered population, and the confirmed non-altered population. RECIST related endpoints such as PFS, ORR, DoR, CBR will be collected.
Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.
时间窗: Within the first 28 day cycle.
Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.
Phase Ib: 2. The number of participants with treatment-related adverse events.
时间窗: From baseline up to approximately 36 months.
Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of participants with treatment-related adverse events.
Phase Ib: 3. The number of participants with treatment-related serious adverse events.
时间窗: From baseline up to approximately 36 months.
Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of participants with treatment-related adverse events.
次要结局
- Phase Ib: 4. PK parameters for Palbociclib, Ribociclib, Abemaciclib: Cmin.(Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 0 is 3 days and Cycle 1 is 28 days).)
- Phase III: 2. Objective Response Rate (ORR).(Up to approximately 47 months.)
- Phase Ib: 3. PK parameters for Palbociclib, Ribociclib, Abemaciclib: AUC0-24h.(Cycle 0 (Cycle 0 is 3 days), Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 1 is 28 days).)
- Phase Ib: 7. PK parameters for capivasertib: Cmin.(Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).)
- Phase III: 7. Participant-reported GHS/QoL in participants(Up to approximately 69 months.)
- Phase Ib: 1. PK parameters for Palbociclib, Ribociclib, Abemaciclib: Cmax.(Cycle 0 (Cycle 0 is 3 days), Cycle 1 Day 11 and Cycle 1 Day 14 (Cycle 1 is 28 days).)
- Phase Ib: 2. PK parameters for Palbociclib, Ribociclib, Abemaciclib: AUC0-72h.(Cycle 0 (Cycle 0 is 3 days).)
- Phase Ib: 5. PK parameters for capivasertib: Cmax.(Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).)
- Phase Ib: 9. Clinical Benefit Rate (CBR) at 24 weeks.(Up to approximately 36 months.)
- Phase III: 4. Duration of Response (DoR).(Up to approximately 47 months.)
- Phase Ib: 6. PK parameters for capivasertib: AUC0-12h.(Cycle 1 Day 11 (Cycle 0 is 3 days and Cycle 1 is 28 days).)
- Phase Ib: 10. Duration of Response (DoR).(Up to approximately 36 months.)
- Phase Ib: 11. Progression Free Survival (PFS).(Up to approximately 36 months.)
- Phase III: 11. The number of participants with serious adverse events.(Up to approximately 69 months.)
- Phase Ib: 8. Objective Response Rate (ORR).(Up to approximately 36 months.)
- Phase III: 1. Overall Survival (OS).(Up to approximately 69 months.)
- Phase III: 3. Progression Free Survival 2 (PFS2)(Up to approximately 69 months.)
- Phase III: 9. Plasma concentration of capivasertib pre- and post-dose.(Up to approximately 69 months.)
- Phase III: 10. The number of participants with adverse events.(Up to approximately 69 months.)
- Phase III: 5. Clinical Benefit Rate (CBR) at 24 weeks.(Up to approximately 47 months.)
- Phase III: 6. Participant-reported physical functioning(Up to approximately 69 months.)
- Phase III: 8. Participant-reported overall side effect bother in participants in the capivasertib arm relative to control arm(Up to approximately 69 months.)